Sebastian is Co-founder and CSO of Scenic Biotech. The Company was founded in 2017 as a spin-out of the Netherlands Cancer Institute and Oxford University. Scenic specialises in evolution inspired medicine for rare diseases by focusing on identifying genetic modifiers for drug intervention. Through licensing from partners, and through their own strategy, Scenic has build a strong intellectual property portfolio covering its Cell-Seq platform technology, its therapeutic targets, and its chemistry. In 2020 Scenic entered into a multi-year strategic collaboration with Genentech, a member of the Roche Group, to discover, develop and commercialise novel therapeutics that target genetic modifiers. The total deal value could exceed US $375M.
Sebastian received his scientific training at The Netherlands Cancer Institute and the Broad Institute of Harvard and MIT. He held a faculty position in Vienna at the CeMM before being appointed as an Associate Professor at the University of Oxford (Nuffield Department of Medicine). There, he held faculty positions as an Associate Member at the Ludwig Institute for Cancer Research and as Director of Functional Genomics at The Target Discovery Institute. Sebastian is a founder and former COO of Haplogen GmbH and a founder and former CEO of Scenic Biotech.